Clorox's results for fiscal Q1 2027 (quarter ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-11-02. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP (net sales)) | $1,905 million (+33.3% vs a year earlier) |
| Diluted EPS (GAAP) | $1.39 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $1.55 |
| Full-year guidance | Reaffirmed |
Guidance
Clorox maintains FY2027 net sales growth of 13–14% and adjusted EPS of $5.70–6.00, now expecting adjusted EPS closer to the low end.
Why this label: 'Maintaining its sales and adjusted EPS outlook ranges' ($5.70-$6.00), though now expecting adjusted EPS closer to the low end.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| net sales growth | FY2027 | 13% to 14% | 13% to 14% |
| adjusted EPS | FY2027 | $5.70 to $6.00 (closer to the low end) | $5.70 to $6.00 |
| diluted EPS | FY2027 | $5.41 to $5.71 | $5.41 to $5.71 |
From the release
Revenue: "Net sales · $ · 1,905 · $ · 1,429"
Earnings per share: "Diluted net earnings per share · $ · 1.39 · $ · 0.16 · $ · 1.55"
net sales growth: "Net sales are still expected to be up 13% to 14% compared to the prior year"
adjusted EPS: "Adjusted EPS is still expected to be between $5.70 and $6.00"
diluted EPS: "Diluted EPS is still expected to be between $5.41 and $5.71"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Net sales rose 33% to $1.91 billion; GOJO added about 15 points.
Source
Clorox earnings release (SEC filing), accession 0000021076-26-000044, filed 2026-11-02.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.